Search

Novo Nordisk's clinical trial for Ziltivekimab, an antibody targeting pro-inflammatory cytokine IL-6, failed 👀 Interestingly, both IL-6 and hsCRP fell with treatment, suggesting an anti-inflammatory effect, yet this did not translate into fewer cardiovascular events. https://t.co/jSZTM1Qxad #NovoNordisk #Ziltivekimab #ClinicalTrials #Nospecificcountriesarementionedinthetweet.

Novo Nordisk announced the failure of its experimental treatment ziltivekimab for cardiovascular events during a phase 3 clinical trial, resulting in a nearly 8% drop in its stock on the Copenhagen Stock Exchange, although the company maintains its commitment to cardiovascular research and continues other trials of the drug. (translated)